The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Long-term follow-up of pirtobrutinib therapy in Waldenström’s macroglobulinemia: the BRUIN trial
Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, discusses long-term follow-up of pirtobrutinib therapy in Waldenström’s macroglobulinemia from the Phase Ib/II BRUIN trial (NCT03740529). Dr Cheah highlights encouraging long-term progression-free survival rates and duration of response, regardless of prior exposure to BTK inhibitors. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
